EANM专家意见:放射生物学经验如何用于临床试验设计?第一部分:回归吸收剂量-反应与阈值吸收剂量基础
EANM放射生物学工作组分析EMA和FDA批准的神经内分泌肿瘤和前列腺癌放射性药物治疗的疗效与毒性,探讨吸收剂量等物理参数与治疗结局的相关性。分析显示平均吸收剂量单独不足以预测治疗反应或毒性,低于某阈值时结局不可预测,高于阈值可提高生物学反应可能性但反应存在平台期。结论认为需更多剂量学数据优化方案,未来研究应整合生物学参数与物理剂量学。
要点
- 平均吸收剂量单独不足以预测靶向放射性核素治疗的反应或毒性。
- 低于某阈值吸收剂量时结局不可预测,高于阈值可提高生物学反应可能性。
- 即使较高吸收剂量下反应仍存在平台期,需其他参数解释结局变异。
核心结论
- 理解放射生物学对优化靶向放射性核素治疗至关重要。
- 需要更多剂量学数据来完善治疗方案。
- 吸收剂量虽关键,但单独不能决定靶向放射性核素治疗结局。
- 未来研究应整合生物学参数与物理剂量学以提高疗效并减少毒性。
研究设计与样本
- 本研究为EANM放射生物学工作组的分析,聚焦EMA和FDA批准的用于神经内分泌肿瘤和前列腺癌的放射性药物。
- 方法为综述靶向放射性核素治疗的临床研究,关注物理参数与治疗结局的关系,并将基础放射生物学原则应用于放射性药物治疗。
主要发现
- 平均吸收剂量单独不足以预测治疗反应或毒性。
- 吸收剂量低于某阈值时结局不可预测,高于该阈值时提高生物学反应的可能性。
- 即使吸收剂量较高,反应仍出现平台期,提示需其他参数解释结局变异。
- 需考虑的额外参数包括靶点表达异质性、解剖疾病位置、(表观)遗传学、DNA修复能力和肿瘤微环境。
局限性
- 原文指出需要更多剂量学数据来完善治疗方案。
- 原文指出未来研究应整合生物学参数与物理剂量学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study by the EANM radiobiology working group aims to analyze the efficacy and toxicity of targeted radionuclide therapy (TRT) using radiopharmaceuticals approved by the EMA and FDA for neuroendocrine tumors and prostate cancer. It seeks to understand the correlation between physical parameters such as absorbed dose and TRT outcomes, alongside other biological factors. METHODS: We reviewed clinical studies on TRT, focusing on the relationship between physical parameters and treatment outcomes, and applying basic radiobiological principles to radiopharmaceutical therapy to identify key factors affecting therapeutic success. RESULTS: The analysis revealed that mean absorbed dose alone is insufficient to predict treatment response or toxicity. For absorbed doses below a certain threshold, outcomes are unpredictable, while doses above this threshold improve the likelihood of biological responses. However, even at higher absorbed doses, response plateaus indicate the need for additional parameters to explain outcome variability, including heterogeneity in target expression, anatomical disease location, (epi)genetics, DNA repair capacity, and the tumor microenvironment, aspects that will be discussed in Part II of this analysis. CONCLUSION: Understanding radiobiology is crucial for optimizing TRT. More dosimetric data is needed to refine treatment protocols. While absorbed dose is critical, it alone does not determine TRT outcomes. Future research should integrate biological parameters with physical dosimetry to enhance efficacy and minimize toxicity.
引用
- Pouget JP, Gabina PM, Herrmann K, et al. EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses. Eur J Nucl Med Mol Imaging. 2024. PMID: 39531084. doi:10.1007/s00259-024-06963-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。